Progress in the Management of Malignant Pleural Mesothelioma in 2017
© 2018 International Association for the Study of Lung Cancer Malignant pleural mesothelioma (MPM) is an uncommon, almost universally fatal, asbestos-induced malignancy. New and effective strategies for diagnosis, prognostication, and treatment are urgently needed. Herein we review the advances in M...
Saved in:
Main Authors: | , , , , , , , , , , , |
---|---|
Other Authors: | |
Format: | Review |
Published: |
2019
|
Subjects: | |
Online Access: | https://repository.li.mahidol.ac.th/handle/123456789/46739 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | Mahidol University |
id |
th-mahidol.46739 |
---|---|
record_format |
dspace |
spelling |
th-mahidol.467392019-08-28T13:12:48Z Progress in the Management of Malignant Pleural Mesothelioma in 2017 Amanda J. McCambridge Andrea Napolitano Aaron S. Mansfield Dean A. Fennell Yoshitaka Sekido Anna K. Nowak Thanyanan Reungwetwattana Weimin Mao Harvey I. Pass Michele Carbone Haining Yang Tobias Peikert Zhejiang Cancer Hospital University of Leicester Università degli Studi di Roma La Sapienza NYU Langone Medical Center University of Western Australia Aichi Cancer Center Hospital and Research Institute Faculty of Medicine, Ramathibodi Hospital, Mahidol University University of Hawaii at Manoa Mayo Clinic Zhejiang Key Laboratory of Diagnosis and Treatment Technology of Thoracic Oncology Medicine © 2018 International Association for the Study of Lung Cancer Malignant pleural mesothelioma (MPM) is an uncommon, almost universally fatal, asbestos-induced malignancy. New and effective strategies for diagnosis, prognostication, and treatment are urgently needed. Herein we review the advances in MPM achieved in 2017. Whereas recent epidemiological data demonstrated that the incidence of MPM-related death continued to increase in United States between 2009 and 2015, new insight into the molecular pathogenesis and the immunological tumor microenvironment of MPM, for example, regarding the role of BRCA1 associated protein 1 and the expression programmed death receptor ligand 1, are highlighting new potential therapeutic strategies. Furthermore, there continues to be an ever-expanding number of clinical studies investigating systemic therapies for MPM. These trials are primarily focused on immunotherapy using immune checkpoint inhibitors alone or in combination with other immunotherapies and nonimmunotherapies. In addition, other promising targeted therapies, including pegylated adenosine deiminase (ADI-PEG20), which focuses on argininosuccinate synthase 1–deficient tumors, and tazemetostat, an enhancer of zeste 2 polycomb repressive complex 2 subunit inhibitor of BRCA1 associated protein 1 gene (BAP1)-deficient tumors, are currently being explored. 2019-08-28T06:12:48Z 2019-08-28T06:12:48Z 2018-05-01 Review Journal of Thoracic Oncology. Vol.13, No.5 (2018), 606-623 10.1016/j.jtho.2018.02.021 15561380 15560864 2-s2.0-85046378485 https://repository.li.mahidol.ac.th/handle/123456789/46739 Mahidol University SCOPUS https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85046378485&origin=inward |
institution |
Mahidol University |
building |
Mahidol University Library |
continent |
Asia |
country |
Thailand Thailand |
content_provider |
Mahidol University Library |
collection |
Mahidol University Institutional Repository |
topic |
Medicine |
spellingShingle |
Medicine Amanda J. McCambridge Andrea Napolitano Aaron S. Mansfield Dean A. Fennell Yoshitaka Sekido Anna K. Nowak Thanyanan Reungwetwattana Weimin Mao Harvey I. Pass Michele Carbone Haining Yang Tobias Peikert Progress in the Management of Malignant Pleural Mesothelioma in 2017 |
description |
© 2018 International Association for the Study of Lung Cancer Malignant pleural mesothelioma (MPM) is an uncommon, almost universally fatal, asbestos-induced malignancy. New and effective strategies for diagnosis, prognostication, and treatment are urgently needed. Herein we review the advances in MPM achieved in 2017. Whereas recent epidemiological data demonstrated that the incidence of MPM-related death continued to increase in United States between 2009 and 2015, new insight into the molecular pathogenesis and the immunological tumor microenvironment of MPM, for example, regarding the role of BRCA1 associated protein 1 and the expression programmed death receptor ligand 1, are highlighting new potential therapeutic strategies. Furthermore, there continues to be an ever-expanding number of clinical studies investigating systemic therapies for MPM. These trials are primarily focused on immunotherapy using immune checkpoint inhibitors alone or in combination with other immunotherapies and nonimmunotherapies. In addition, other promising targeted therapies, including pegylated adenosine deiminase (ADI-PEG20), which focuses on argininosuccinate synthase 1–deficient tumors, and tazemetostat, an enhancer of zeste 2 polycomb repressive complex 2 subunit inhibitor of BRCA1 associated protein 1 gene (BAP1)-deficient tumors, are currently being explored. |
author2 |
Zhejiang Cancer Hospital |
author_facet |
Zhejiang Cancer Hospital Amanda J. McCambridge Andrea Napolitano Aaron S. Mansfield Dean A. Fennell Yoshitaka Sekido Anna K. Nowak Thanyanan Reungwetwattana Weimin Mao Harvey I. Pass Michele Carbone Haining Yang Tobias Peikert |
format |
Review |
author |
Amanda J. McCambridge Andrea Napolitano Aaron S. Mansfield Dean A. Fennell Yoshitaka Sekido Anna K. Nowak Thanyanan Reungwetwattana Weimin Mao Harvey I. Pass Michele Carbone Haining Yang Tobias Peikert |
author_sort |
Amanda J. McCambridge |
title |
Progress in the Management of Malignant Pleural Mesothelioma in 2017 |
title_short |
Progress in the Management of Malignant Pleural Mesothelioma in 2017 |
title_full |
Progress in the Management of Malignant Pleural Mesothelioma in 2017 |
title_fullStr |
Progress in the Management of Malignant Pleural Mesothelioma in 2017 |
title_full_unstemmed |
Progress in the Management of Malignant Pleural Mesothelioma in 2017 |
title_sort |
progress in the management of malignant pleural mesothelioma in 2017 |
publishDate |
2019 |
url |
https://repository.li.mahidol.ac.th/handle/123456789/46739 |
_version_ |
1763487242303569920 |